A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley, Laura Cummings, Jeffrey Middleton, M Ward, Timothy H Backen, Alison C Clamp, Andrew R Dawson, Martin J Farmer, H Fisher, N Halbert, G
Horsley, Laura
Cummings, Jeffrey
Middleton, M
Ward, Timothy H
Backen, Alison C
Clamp, Andrew R
Dawson, Martin J
Farmer, H
Fisher, N
Halbert, G
Citations
Altmetric:
Abstract
4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is a water-soluble mitochondrial toxin that binds to adenine nucleotide translocase in the inner mitochondrial membrane, thereby targeting cell proliferation. This phase 1 study investigated safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics (PK) of GSAO as a daily 1-h infusion for 5 days a week for 2 weeks in every three. Pharmacodynamics of GSAO was evaluated by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and circulating markers of angiogenesis.
Authors
Horsley, Laura
Cummings, Jeffrey
Middleton, M
Ward, Timothy H
Backen, Alison C
Clamp, Andrew R
Dawson, Martin J
Farmer, H
Fisher, N
Halbert, G
Halford, S
Harris, A
Hasan, Jurjees
Hogg, P
Kumaran, Gireesh C
Little, R
Parker, G
Potter, Paula
Saunders, Mark P
Roberts, C
Shaw, Danielle
Smith, Nigel K
Smythe, J
Taylor, A
Turner, H
Watson, Y
Dive, Caroline
Jayson, Gordon C
Cummings, Jeffrey
Middleton, M
Ward, Timothy H
Backen, Alison C
Clamp, Andrew R
Dawson, Martin J
Farmer, H
Fisher, N
Halbert, G
Halford, S
Harris, A
Hasan, Jurjees
Hogg, P
Kumaran, Gireesh C
Little, R
Parker, G
Potter, Paula
Saunders, Mark P
Roberts, C
Shaw, Danielle
Smith, Nigel K
Smythe, J
Taylor, A
Turner, H
Watson, Y
Dive, Caroline
Jayson, Gordon C
Description
Date
2013-12
Publisher
Collections
Keywords
Type
Article
Citation
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. 2013, 72 (6):1343-52 Cancer Chemother Pharmacol